

## REVIEW

# Therapeutic potential of targeting hydrogen peroxide metabolism in the treatment of brain ischaemia

Marta Armogida<sup>1</sup>, Robert Nisticò<sup>1,2</sup> and Nicola Biagio Mercuri<sup>1,3</sup><sup>1</sup>Laboratory of Experimental Neurology, Fondazione Santa Lucia IRCCS, Rome, Italy,<sup>2</sup>Department of Pharmacobiology, University of Calabria, Rende (CS), Italy, and <sup>3</sup>Department of Neuroscience, University of Rome 'Tor Vergata', Rome, Italy**Correspondence**

Prof Nicola Biagio Mercuri,  
Laboratory of Experimental  
Neurology, Fondazione Santa  
Lucia IRCCS, Centro Europeo di  
Ricerca sul Cervello (CERC), Via  
del Fosso di Fiorano 64, 00143  
Rome, Italy. E-mail:  
mercurin@med.uniroma2.it

**Keywords**

brain ischaemia; hydrogen  
peroxide; neuroprotection;  
catalase; electrophysiology

**Received**

26 October 2011

**Revised**

6 February 2012

**Accepted**

14 February 2012

For many years after its discovery, hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) was viewed as a toxic molecule to human tissues; however, in light of recent findings, it is being recognized as an ubiquitous endogenous molecule of life as its biological role has been better elucidated. Indeed, increasing evidence suggests that H<sub>2</sub>O<sub>2</sub> may act as a second messenger with a pro-survival role in several physiological processes. In addition, our group has recently demonstrated neuroprotective effects of H<sub>2</sub>O<sub>2</sub> on *in vitro* and *in vivo* ischaemic models through a catalase (CAT) enzyme-mediated mechanism. Therefore, the present review summarizes experimental data supporting a neuroprotective potential of H<sub>2</sub>O<sub>2</sub> in ischaemic stroke that has been principally achieved by means of pharmacological and genetic strategies that modify either the activity or the expression of the superoxide dismutase (SOD), glutathione peroxidase (GPx) and CAT enzymes, which are key regulators of H<sub>2</sub>O<sub>2</sub> metabolism. It also critically discusses a translational impact concerning the role played by H<sub>2</sub>O<sub>2</sub> in ischaemic stroke. Based on these data, we hope that further research will be done in order to better understand the mechanisms underlying H<sub>2</sub>O<sub>2</sub> functions and to promote successful H<sub>2</sub>O<sub>2</sub> signalling based therapy in ischaemic stroke.

**Abbreviations**

3-AT, 3-amino-1,2,4-triazole; ACSF, artificial cerebral spinal fluid; BSO, buthionine sulfoximine; CAT, catalase; DA, dopamine; DHE, dihydroethidium; fEPSP, field excitatory postsynaptic potential; GPx, glutathione peroxidase; HIF, hypoxia-inducible factor; IPC, ischaemic preconditioning; IR, ischaemia-reperfusion; K<sub>ATP</sub>, ATP-sensitive K<sup>+</sup> channel; MCAo, middle cerebral artery occlusion; MCS, mercaptosuccinate; mTOR, mammalian target of rapamycin; NF, nuclear factor; NOS, nitric oxide synthase; O<sub>2</sub>, molecular oxygen; O<sub>2</sub><sup>-</sup>, superoxide anion; OGD, oxygen/glucose-deprivation; •OH, hydroxyl radical; PGC1α, PPARγ coactivator1α; PI3K, phosphatidylinositol 3-kinase; PPARγ, peroxisome proliferator-activated receptor; Prx, peroxiredoxin; ROS, reactive oxygen species; SNc, substantia nigra pars compacta; SOD, superoxide dismutase; TDP, thiolate-dependent phosphatase; Tg(CAT), transgenic mouse over-expressing catalase; TRP, transient receptor potential; WT, wild-type

**Nomenclature**

The drug/molecular target nomenclature used in this review conforms to the *British Journal of Pharmacology's Guide to Receptors and Channels* (Alexander *et al.*, 2011), where applicable.

**Historical notes**

The history of H<sub>2</sub>O<sub>2</sub> began in 1818 when it was discovered by Thénard who named it *eau oxygénée* (Thénard, 1818). Since the mid-1800s, H<sub>2</sub>O<sub>2</sub> has been marketed for a wide variety of uses, including non-polluting bleaching, oxidizing agent,

disinfectant in food processing and even fuel for rockets. The presence of H<sub>2</sub>O<sub>2</sub> in living systems was identified in 1856 (Schoenbein, 1856). However, it was only in 1894 that 100% pure H<sub>2</sub>O<sub>2</sub> was first extracted from H<sub>2</sub>O by Wolfenstein through vacuum distillation (Wolfenstein, 1894). In 1888, the first medical use of H<sub>2</sub>O<sub>2</sub> was described by Love as efficacious in treating numerous diseases, including scarlet fever, diphtheria, nasal catarrh, acute coryza, whooping cough, asthma hay fever and tonsillitis (Love, 1888). Similarly, Oliver and collaborators reported that intravenous injection of H<sub>2</sub>O<sub>2</sub> was efficacious in treating influenza pneumonia in the epidemic following World War I (Oliver *et al.*, 1920). Despite its beneficial effects, in the 1940s medical interest in further research on H<sub>2</sub>O<sub>2</sub> was slowed down by the emerging development of new prescription medicines. In the early 1960s, Urschel, and later Finney and co-workers, conducted several studies on myocardial ischaemia demonstrating a rescue afforded by H<sub>2</sub>O<sub>2</sub>, thereby suggesting an important protective action of H<sub>2</sub>O<sub>2</sub> against ischaemia-reperfusion (IR) injury (Finney *et al.*, 1967; Urschel, 1967). Notably, Farr is generally considered to be the pioneer of 'oxidative therapy' by proposing intravenous infusion of H<sub>2</sub>O<sub>2</sub> to treat a wide variety of diseases (Farr, 1988). Later, Willhelm promoted the therapeutic use of H<sub>2</sub>O<sub>2</sub> to treat cancer, skin diseases, polio and bacteria-related mental illness. He defined H<sub>2</sub>O<sub>2</sub> as 'God's given immune system' (Willhelm, 1989; Green, 1998). Another player in the H<sub>2</sub>O<sub>2</sub> story was Grotz, who obtained pain relief by testing H<sub>2</sub>O<sub>2</sub> on himself to treat his arthritis pain (Green, 1998).

## Metabolism of H<sub>2</sub>O<sub>2</sub>

H<sub>2</sub>O<sub>2</sub> is mainly generated as a by-product of aerobic metabolism in the mitochondria (Fridovich, 1995), where formation of the superoxide anion (O<sub>2</sub><sup>-</sup>) results from partial reduction of molecular oxygen (O<sub>2</sub>) in the electron transport chain. A smaller amount of O<sub>2</sub><sup>-</sup> is also produced by enzymatic activities including NOS, xanthine oxidase, NADPH oxidase, dehydrogenases and peroxidases (Boveris and Chance, 1973; Rhee, 2006; Bao *et al.*, 2009; Finkel, 2011). In addition, enzymes such as superoxide dismutase (SOD), in its three isoforms (cytosolic, extracellular Cu,Zn-SOD, and mitochondrial Mg-SOD), are also responsible for H<sub>2</sub>O<sub>2</sub> production from O<sub>2</sub><sup>-</sup> (Graham *et al.*, 1978; Fridovich, 1995). The dismutation reaction catalyzed by SOD is as follows: 2O<sub>2</sub><sup>-</sup> + 2H<sup>+</sup> → H<sub>2</sub>O<sub>2</sub> + O<sub>2</sub>. H<sub>2</sub>O<sub>2</sub> is also generated as a direct by-product of MAO enzyme activity. In fact, the oxidative deamination reaction catalyzed by MAO requires O<sub>2</sub> to degrade bioamines and produces H<sub>2</sub>O<sub>2</sub>, the corresponding aldehyde and ammonia according to the overall equation: R-CH<sub>2</sub>-NH<sub>2</sub> + O<sub>2</sub> + H<sub>2</sub>O → H<sub>2</sub>O<sub>2</sub> + R-CHO + NH<sub>3</sub>, where R stands for alkyl group (Tipton, 1968; Tipton *et al.*, 2004). Moreover, H<sub>2</sub>O<sub>2</sub> generation can be the result of p66<sup>Shc</sup> enzyme activity (Giorgio *et al.*, 2007). H<sub>2</sub>O<sub>2</sub> is subsequently converted to H<sub>2</sub>O by scavenger enzymes such as cytosolic and mitochondrial glutathione peroxidase (GPx) which catalyzes the reaction: H<sub>2</sub>O<sub>2</sub> + 2GSH → 2H<sub>2</sub>O + GSSG, or decomposed in peroxisomes to H<sub>2</sub>O and O<sub>2</sub> by catalase (CAT) according to the equation: 2H<sub>2</sub>O<sub>2</sub> → 2H<sub>2</sub>O + O<sub>2</sub>; the latter has been observed to be more effective than GPx in detoxifying neurons from H<sub>2</sub>O<sub>2</sub> (Halliwell, 1999; Dringen

*et al.*, 2005). A smaller contribution to regulate H<sub>2</sub>O<sub>2</sub> levels also comes from thioredoxins as well as peroxiredoxins (Prx) (Rhee, 2006; Mishina *et al.*, 2011). H<sub>2</sub>O<sub>2</sub> metabolism is highly dynamic: its intracellular concentration reflects the balance between processes of generation and removal (Halliwell, 1999). Actually, there are no certain measurements of either intracellular or extracellular H<sub>2</sub>O<sub>2</sub> concentration. Many attempts to address this point have failed due to high cellular peroxidase-mediated depletion and technical limitations of H<sub>2</sub>O<sub>2</sub>-sensitive fluorescent dyes (Rice, 2011). However, *in vivo* microdialysis has been used to try to determine the extracellular production of H<sub>2</sub>O<sub>2</sub> in the brain during IR. A fourfold rise in H<sub>2</sub>O<sub>2</sub> from basal levels has been detected in dialysates from the rat anterior lateral striatum during reperfusion after 30 min of global forebrain ischaemia (approximately 100 μM at the peak during reperfusion phase) (Hyslop *et al.*, 1995). Similarly, fluorometry of 2',7'-dichlorofluorescein oxidation coupled with *in vivo* microdialysis have been applied in the gerbil hippocampal CA1 region in order to monitor changes in H<sub>2</sub>O<sub>2</sub> concentration during IR. A marked and rapid increase in H<sub>2</sub>O<sub>2</sub> level was recorded in the reperfusion phase, although to a lesser degree (range 1–3 μM), which continued to increase in dialysates until 30 min of reperfusion after transient ischaemia (5 min) (Lei *et al.*, 1998). By means of mathematical models, upper limits (100 nM to 1 μM) have been recently estimated to be 10 to 100-fold lower than exogenously applied concentrations (Antunes and Cadenas, 2000), indicating a signalling action of H<sub>2</sub>O<sub>2</sub> at 15–150 μM without any oxidative damage (Rice, 2011). Noteworthy, concentrations of H<sub>2</sub>O<sub>2</sub> that can be reached in rat vascular smooth muscle cells exposed to IR insult are likely to be higher than 1 mM (Sundaresan *et al.*, 1995). In spite of this, we are still searching for effective tools to detect the real concentration of H<sub>2</sub>O<sub>2</sub> in both the intracellular and extracellular compartments of the brain. Of note, 1–3 mM H<sub>2</sub>O<sub>2</sub> has been used for investigations of synaptic function and intracellular Ca<sup>2+</sup> changes in the hippocampus (Pellmar, 1987; Nisticò *et al.*, 2008; Gerich *et al.*, 2009). These exogenous concentrations appear to have pathophysiological relevance. Conversely, the other important question related to the toxicity of relatively high extracellular concentrations of H<sub>2</sub>O<sub>2</sub> has not really been solved yet. In fact, it has been reported that hippocampal neurons from primary culture tolerate 300 μM H<sub>2</sub>O<sub>2</sub> for at least 30 min (Miller *et al.*, 2005). However, it has to be considered that the concentration of H<sub>2</sub>O<sub>2</sub> that reaches the intracellular *milieu* could be significantly lower than that superfused on tissue. Firstly, H<sub>2</sub>O<sub>2</sub> transport might be limited by lipid membrane composition and diffusion rate (Antunes and Cadenas, 2000); secondly, it might be differentially transported by aquaporins and other channels (Bienert *et al.*, 2007). Therefore, the high concentrations used in *in vitro* experiments may not reflect the content reached in the intracellular compartment that could be markedly lower.

## H<sub>2</sub>O<sub>2</sub>: a paradox player

### *Emerging role of H<sub>2</sub>O<sub>2</sub> in the physiological control of cell functioning*

H<sub>2</sub>O<sub>2</sub> is often considered a toxic molecule for a wide range of living systems. It has also been reported to be implicated in

severe pathological conditions such as cancer, ischaemia and neurodegenerative diseases (Halliwell and Gutteridge, 1999; Halliwell *et al.*, 2000). However, robust evidence has led to re-evaluation of its role as an important regulatory signal in a variety of biological processes (Sundaresan *et al.*, 1995; Sen and Packer, 1996; Rhee, 2006; Stone and Yang, 2006; D'Autréaux and Toledano, 2007; Miller *et al.*, 2007; Veal *et al.*, 2007; Gerich *et al.*, 2009; Groeger *et al.*, 2009; Rice, 2011), thus suggesting that the deleterious role of this oxidant has been overestimated. In particular, H<sub>2</sub>O<sub>2</sub> can modulate synaptic transmission (Pellmar, 1987; Katsuki *et al.*, 1997; Chen *et al.*, 2001; Avshalumov *et al.*, 2003; 2008) and plasticity in the rodent brain (Colton *et al.*, 1989; Auerbach and Segal, 1997; Klann and Thiels, 1999; Kamsler and Segal, 2003). H<sub>2</sub>O<sub>2</sub> is also implicated in intracellular Ca<sup>2+</sup> signalling and organelle function modulation in rat hippocampus (Gerich *et al.*, 2009). Additional evidence has indicated a dynamic modulation exerted by H<sub>2</sub>O<sub>2</sub> in the nigrostriatal dopaminergic (DAergic) system. In fact, it inhibits substantia nigra DAergic neurons and striatal DA release by activating ATP-sensitive K<sup>+</sup> channels (K<sub>ATP</sub>) (Chen *et al.*, 2001; Avshalumov *et al.*, 2003; 2005; 2008). Of note, H<sub>2</sub>O<sub>2</sub> may also act as an excitatory agent on non-DAergic neurons by inducing transient receptor potential (TRP) channel (subgroup melastatin type TRPM2) activation (Rice, 2011).


### *Mechanisms, targets and outcomes of H<sub>2</sub>O<sub>2</sub> signalling: concentration as a determining factor*

H<sub>2</sub>O<sub>2</sub> is a chemical messenger able to spread locally in and out of the cell. It passes across cell membranes through specific aquaporin 3 channels or freely, like other diffusible messengers (such as NO, carbon monoxide and hydrogen sulphide) (Bierner *et al.*, 2006; 2007; Miller *et al.*, 2010). In chemical terms, H<sub>2</sub>O<sub>2</sub> is poorly reactive and is more stable than other reactive oxygen species (ROS) because it is not itself a free radical. Therefore, it is able to survive long enough to act distant from its place of generation. It is widely accepted that low levels of H<sub>2</sub>O<sub>2</sub> target sulfhydryl groups of protein cysteine residues by oxidizing them and consequently, affecting the activity of key signal transduction kinases and phosphatases, thus representing the 'signalling face' of H<sub>2</sub>O<sub>2</sub> (Rhee *et al.*, 2000; Giorgio *et al.*, 2007) (Figure 1). In fact, H<sub>2</sub>O<sub>2</sub> may affect cell-signalling survival pathways by reversibly inhibiting many proteins (i.e. phosphatases). Phosphatases are potent negative regulators of the survival pathways that transduce their signal through phosphorylation of key proteins (Groeger *et al.*, 2009). For instance, H<sub>2</sub>O<sub>2</sub> promotes the cell survival signalling cascade [e.g. phosphatidylinositol 3-kinase (PI3K)/AKT] by inactivating Tyr and Ser/Thr phosphatases (e.g. PTEN, FAK, SHP2, CDC25, PTP1B) (Giorgio *et al.*, 2007). On the other hand, H<sub>2</sub>O<sub>2</sub> is also responsible for the activation of MAPKs (e.g. ERK1/2, p38 MAPK) and for the modulation of transcription factors involved in cellular response to stress stimuli such as hypoxia and oxidative stress (Giorgio *et al.*, 2007; Oliveira-Marques *et al.*, 2009). Under hypoxia, H<sub>2</sub>O<sub>2</sub> may affect the activity of the transcription factor hypoxia-inducible factor (HIF)-1 $\alpha$  by inhibiting HIF-1 $\alpha$  DNA-binding activity and accumulation (Groeger *et al.*, 2009). The regulatory role played by H<sub>2</sub>O<sub>2</sub> on the nuclear factor (NF)- $\kappa$ B pathway is still controversial: among the described actions, an important one is the increase

of DNA-binding activity of NF- $\kappa$ B through the H<sub>2</sub>O<sub>2</sub>-induced inactivation of the enzyme histone deacetylase which is implicated in chromatin remodelling (Groeger *et al.*, 2009; Oliveira-Marques *et al.*, 2009). Recently, it has also been demonstrated that H<sub>2</sub>O<sub>2</sub> is also implicated in several growth factor-triggered signals (Stone and Yang, 2006; Valko *et al.*, 2007). Further evidence has shown that H<sub>2</sub>O<sub>2</sub> stimulates the renal epithelial Na<sup>+</sup> channel through a PI3K pathway, thus suggesting its involvement in systemic blood pressure homeostasis (Ma, 2011). Notably, cell damage, death (either by necrosis or apoptosis) and senescence appear to be induced only by high levels of H<sub>2</sub>O<sub>2</sub> (Giorgio *et al.*, 2007; Oliveira-Marques *et al.*, 2009). H<sub>2</sub>O<sub>2</sub> may induce apoptosis in neuronal cells by inhibiting the mammalian target of rapamycin signalling (Chen *et al.*, 2010). In endothelial cells, an excess of H<sub>2</sub>O<sub>2</sub> activates Fas and JNK pathways in apoptosis (Cai, 2005). H<sub>2</sub>O<sub>2</sub> oxidizes, in a manner to cause cytotoxic damage to biological macromolecules (such as lipids, proteins and DNA), only if converted to the highly reactive hydroxyl radical ( $\bullet$ OH) (Winterbourn, 2008; Oliveira-Marques *et al.*, 2009). The latter is generated via Fenton reaction by H<sub>2</sub>O<sub>2</sub> interaction with free transition metals (mostly reduced Fe<sup>2+</sup> and Cu<sup>+</sup> ions) (Halliwell, 1992; Cohen, 1994). In its dual role as an indispensable signal molecule and a potential threat for biological components, H<sub>2</sub>O<sub>2</sub> plays the double-faced role of 'Dr. Jekyll and Mr. Hyde' (Gough and Cotter, 2011). Indeed, a real H<sub>2</sub>O<sub>2</sub> paradox exists: on one hand, in low amounts H<sub>2</sub>O<sub>2</sub> has a physiological role in the homeostatic maintenance of normal cell functioning; on the other hand, high amounts of H<sub>2</sub>O<sub>2</sub> can be harmful for cells (Figure 1).

### *H<sub>2</sub>O<sub>2</sub> sensing during ischaemic injury: implications for neuroprotection*

In order to maintain H<sub>2</sub>O<sub>2</sub> physiological signalling function, both intracellular and extracellular concentrations of H<sub>2</sub>O<sub>2</sub> need to be constantly maintained at a level below toxicity threshold via an accurate and complex metabolic regulation (Halliwell, 1999; Góth, 2006). In mammalian cells, redox sensor function has been suggested for Prx-1, thiol peroxidases and thiolate-dependent phosphatases, which may affect H<sub>2</sub>O<sub>2</sub> signalling fluxes (Stone and Yang, 2006; D'Autréaux and Toledano, 2007). More importantly, specific responses to H<sub>2</sub>O<sub>2</sub>-induced oxidative stress are regulated in eukaryotic cells by acetylation or deacetylation of transcription factors of the class O forkhead box family, which could lead to either cell death or a quiescent cellular state (Brunet *et al.*, 2004; van der Horst *et al.*, 2004). Moreover, low levels of H<sub>2</sub>O<sub>2</sub> stimulate p53 tumour suppressor-mediated antioxidant response by activating antioxidant genes (e.g. GPx, SOD, sestrins), while high levels of it induce p53-dependent apoptosis (Veal *et al.*, 2007). The peroxisome proliferator-activated receptor $\gamma$  (PPAR $\gamma$ ) coactivator1 $\alpha$  (PGC1 $\alpha$ ) also establishes a crucial link between mitochondrial production of ROS and anti-ROS programmes by regulating H<sub>2</sub>O<sub>2</sub>-inducible antioxidant enzymes (SOD, CAT, GPx) (St-Pierre *et al.*, 2006; D'Autréaux and Toledano, 2007). Strong evidence now suggests PPAR $\gamma$  agonists as new therapeutic targets for the treatment of IR injury (Giaginis *et al.*, 2008; Kaundal and Sharma, 2010); similarly, PGC1 $\alpha$  could be a candidate for drug action as well. Interestingly, a dramatic accumulation of ROS has been reported as an additional side effect of IR (Flamm *et al.*, 1978; Traystman *et al.*, 1991). Indeed, ROS, including H<sub>2</sub>O<sub>2</sub>,



**Figure 1**

The H<sub>2</sub>O<sub>2</sub> paradox in the regulation of cell signalling transduction cascade. The H<sub>2</sub>O<sub>2</sub> biological functions depend on the concentration of H<sub>2</sub>O<sub>2</sub> within the cell. At low concentrations, H<sub>2</sub>O<sub>2</sub> acts as a messenger in a great variety of biological processes contributing to cell survival. In high concentrations, H<sub>2</sub>O<sub>2</sub> can cause deleterious effects, mainly via •OH-derived radicals, by inducing a severe oxidative stress and cell death. Accordingly, a crucial target of H<sub>2</sub>O<sub>2</sub> double-faced action is represented by the tumour suppressor protein p53 which can be either activated by low levels of H<sub>2</sub>O<sub>2</sub>, thus triggering an antioxidant response (anti-apoptotic programme), or inhibited by high levels of H<sub>2</sub>O<sub>2</sub> leading to programmed cell death (pro-apoptotic programme) respectively.

are considered prime mediators of neuronal injury. During an IR episode, the oxidative stress either could result from increased ROS production or decreased activity of cellular defence systems (White *et al.*, 2000; Valko *et al.*, 2007). On the other hand, with regard to the ischaemia, experimental evidence also suggests that H<sub>2</sub>O<sub>2</sub> elimination by CAT may provide an alternative source for O<sub>2</sub>, causing neuroprotection in hypoxic conditions (Topper *et al.*, 1996; Auerbach and Segal, 1997; Klann and Thiels, 1999).

### Effects of H<sub>2</sub>O<sub>2</sub> on rodent *in vitro* and *in vivo* models of brain ischaemia

Valid experimental approaches are required for the development of a successful therapy for ischaemic stroke. Although

models of brain ischaemia have been the main source of a plethora of information on stroke, these models often fail to mimic the complex scenario of stroke as observed clinically. Such limitations should be carefully considered when designing experiments to ensure translation of preclinical data to the clinic (Lipsanen and Jolkkonen, 2011). In our studies, we chose three different widely accepted experimental models of brain ischaemia: hypoxia and oxygen/glucose deprivation (OGD) as *in vitro* brain ischaemia models, and middle cerebral artery occlusion (MCAo) as *in vivo* brain ischaemia model (Lipton, 1999). In hypoxia and OGD *in vitro* models, ischaemic stroke was mimicked by applying oxygen-deprived and oxygen/glucose-deprived artificial cerebral spinal fluid (ACSF) media, respectively, over a brain slice and gassing it with nitrogen (95% N<sub>2</sub> to 5% CO<sub>2</sub>). At the end of the insult, the slice was again perfused with normal oxygenated (95% O<sub>2</sub>



to 5% CO<sub>2</sub>) ACSF medium. Both models allowed us to rapidly screen bath-applied compounds by determining their effect as well as their mechanism of action against the acute damage during electrophysiological recording. Among the *in vivo* models currently used in stroke research, the transient focal ischaemia model (whole animal) represented by MCAo has been extensively used (Durukan and Tatlisumak, 2009). MCAo requires microsurgery to perform the filamentous intraluminal occlusion of the middle cerebral artery. This technique presents several advantages: it models focal infarction in a large vascular territory of the brain, where it is possible to distinguish core and penumbra regions; it is relatively less invasive because it does not require craniotomy; and it allows investigations after reperfusion.

### Substantia nigra

DAergic neurons of the substantia nigra pars compacta (SNc) are highly sensitive to metabolic stress. Very likely, as a safety mechanism to preserve energy consumption, these neurons typically respond to energy deprivation with membrane hyperpolarization, mainly through opening of K<sub>ATP</sub> channels (Mercuri *et al.*, 1994). After a prolonged hypoxia, this early hyperpolarization is followed by a profound and irreversible depolarization, due to opening of cationic conductance and failure of Na<sup>+</sup>/K<sup>+</sup>-ATPase pump (Mercuri *et al.*, 1994; Lees and Leong, 1995). Moreover, previous observations have shown that H<sub>2</sub>O<sub>2</sub> may act as a supplementary source of O<sub>2</sub> in an isolated neonatal rat spinal cord preparation *in vitro* (Walton and Fulton, 1983) and a recovery of the synaptic function by H<sub>2</sub>O<sub>2</sub> during hypoxic insult in rat hippocampal slices (Fowler, 1997). In the past years, we have used both electrophysiological and morphological techniques to investigate a possible protective role of H<sub>2</sub>O<sub>2</sub> in DAergic neurons of the rat SNc exposed to hypoxic insult (Geracitano *et al.*, 2005). Notably, H<sub>2</sub>O<sub>2</sub> reversed membrane hyperpolarization and blocked spontaneous firing associated with oxygen-deprivation in DAergic neurons (Figure 2A,B). In contrast, in normoxic conditions, H<sub>2</sub>O<sub>2</sub> (3 mM) blocked the spontaneous activity of the DAergic cells by inducing a K<sub>ATP</sub> channels-dependent outward current that was sensitive to tolbutamide (1 mM) (a non-selective blocker of K<sub>ATP</sub> channels) (Figure 2C). Of note, H<sub>2</sub>O<sub>2</sub> decreased the hypoxia-mediated outward current in a concentration-dependent manner. Conversely, H<sub>2</sub>O<sub>2</sub> did not counteract membrane hyperpolarization associated with hypoglycaemia. The superfusion of H<sub>2</sub>O<sub>2</sub> (3 mM) during prolonged hypoxia (40 min) rescued most of the DAergic neurons from irreversible firing inhibition. Noteworthy, in the presence of 3-amino-1,2,4-triazole (3-AT, 30 mM), a specific inhibitor of CAT activity (Appleman *et al.*, 1956; Margoliash and Novogrodsky, 1958), H<sub>2</sub>O<sub>2</sub> was unable to decrease hypoxia-mediated outward current and thus restore the spontaneous firing rate (Figure 2D). The protective effects of H<sub>2</sub>O<sub>2</sub> have been confirmed by inhibition of the hypoxia-induced release of cytochrome *c*, a well-known early indicator of apoptotic pathway activation (Fujimura *et al.*, 2000; Sims and Anderson, 2002). These findings suggest a protective action of H<sub>2</sub>O<sub>2</sub> in hypoxic DAergic neurons by serving as a supplementary source of O<sub>2</sub>, through its degradation by CAT and thus, interfering with K<sub>ATP</sub> channels opening consequent to O<sub>2</sub> deprivation (Figure 2E). On the other hand, under normoxic conditions, H<sub>2</sub>O<sub>2</sub> (3 mM) induced by itself a tolbutamide-


sensitive outward current in DAergic neurons. This outward response is due to the opening of K<sub>ATP</sub> channels by a direct action of H<sub>2</sub>O<sub>2</sub> on the channels (Avshalumov *et al.*, 2005) (Figure 2E).

### Hippocampus

The CA1 hippocampal pyramidal neurons are known to be very vulnerable to IR insult (Kirino, 1982; Pulsinelli *et al.*, 1982; Smith *et al.*, 1984). Recently, we have evaluated the neuroprotective role of exogenous H<sub>2</sub>O<sub>2</sub> and of the modification in its endogenous levels by the pharmacological modulation of H<sub>2</sub>O<sub>2</sub> producing (Cu,Zn-SOD) and degrading enzymes (CAT and GPx) against *in vitro* OGD damage in hippocampal slices. Similar to what has been observed in a previous report (Fowler, 1997), we found that the irreversible depression of fEPSPs caused by *in vitro* OGD was abolished when slices were treated with H<sub>2</sub>O<sub>2</sub> (3 mM, 30 min) during OGD exposure (30 min) in CA1 region (Nisticò *et al.*, 2008) (Figure 3A). Importantly, the neuroprotective effects of H<sub>2</sub>O<sub>2</sub> were still maintained even when applied 7 min after the ischaemic conditions had already been imposed (Figure 3B). Again, the rescuing action of H<sub>2</sub>O<sub>2</sub> (3 mM) was mediated by the CAT-induced formation of O<sub>2</sub>. In fact, a pretreatment of the slices with the CAT inhibitor (3-AT, 20 mM) blocked this protective effect (Figure 3C). Moreover, we have shown that an increase of the endogenous levels of H<sub>2</sub>O<sub>2</sub>, due to a combined bath-application of mercaptosuccinate (MCS, 1 mM) (a potent and specific inhibitor of selenium-dependent GPx) (Chaudiere *et al.*, 1984), and Cu,Zn-SOD (120 U·mL<sup>-1</sup>), which augments H<sub>2</sub>O<sub>2</sub> production, limited the OGD-induced irreversible depression of fEPSPs. These results were in line with previous observation of neuroprotection afforded by H<sub>2</sub>O<sub>2</sub> against hypoxic insult on DAergic cells (Geracitano *et al.*, 2005) and propose novel therapeutic strategies based on increasing the endogenous tissue levels of H<sub>2</sub>O<sub>2</sub> in the ischaemic brain.

### Striatum

Little information is as yet available as to whether H<sub>2</sub>O<sub>2</sub> may contribute to neuroprotection in *in vivo* brain ischaemia because its systemic infusion induces gas embolism which can cause additional occlusions of the vessels. As a matter of fact, there is O<sub>2</sub> formation in the vessels due to the ubiquitous localization of the CAT enzyme (Watt *et al.*, 2004; French *et al.*, 2010). As it was not feasible to inject H<sub>2</sub>O<sub>2</sub> intravenously, our aim was to examine the effect of increasing the endogenous levels of H<sub>2</sub>O<sub>2</sub> in an *in vivo* model of brain ischaemia. This increase has been accomplished through inhibition of GPx by systemic intraperitoneal administration of MCS. We observed that MCS (1.5–150 mg·kg<sup>-1</sup>) dose dependently decreased brain infarct damage produced by transient (2 h) MCAo in rat (Amantea *et al.*, 2009) (Figure 3D). Interestingly, neuroprotection was observed when MCS was administered 15 min before the ischaemic insult, and no protection was detected when the drug was injected 1 h before MCAo or upon reperfusion. Such results were in accordance with another study showing a prolongation of survival time of rats following 20 min brain ischaemia when pretreated with buthionine sulfoximine (BSO), a drug that is a glutathione depletor (Vanella *et al.*, 1993). BSO could



## Figure 2

Electrophysiological effects of H<sub>2</sub>O<sub>2</sub> on SNc DAergic neurons. (A) Hypoxia caused firing discharge inhibition in current-clamp sharp electrode intracellular recordings ( $n = 11$ ) (upper trace), and an outward current followed by a transient post-hypoxic outward current in voltage-clamp ( $V_{\text{holding}} = -60$  mV) intracellular recordings ( $n = 8$ ) (lower trace). (B) During hypoxia, after H<sub>2</sub>O<sub>2</sub> (3 mM) perfusion, a transient hyperpolarization followed by complete firing recovery was observed ( $n = 6$ ) (upper trace); the hypoxia-induced outward current was reverted by H<sub>2</sub>O<sub>2</sub> ( $n = 6$ ) (lower trace). (C) In normoxia, H<sub>2</sub>O<sub>2</sub> (3 mM) induced a reversible outward current ( $n = 4$ ) (upper trace); the K<sub>ATP</sub> channel antagonist tolbutamide (1 mM) inhibited such current (lower trace). (D) Hypoxia induced outward current in the presence of CAT inhibitor 3-AT (30 mM); in the same neuron, such current is increased, not prevented in the presence of H<sub>2</sub>O<sub>2</sub> ( $n = 8$ ) in whole-cell patch-clamp voltage-clamp recordings ( $P < 0.01$ ). Data in the graphs are expressed as means  $\pm$  SEM. Bars indicate the exposure time to compounds and OGD [A–D modified from Geracitano *et al.* (2005); copyright *J Physiol*, used with permission]. (E) Hypothesized mechanism of neuroprotection afforded by H<sub>2</sub>O<sub>2</sub> against hypoxic insult in SNc DAergic neurons. In normoxic conditions, H<sub>2</sub>O<sub>2</sub> causes direct K<sub>ATP</sub> channel opening (we believe that this is a generic cellular defensive response to insults). Also, hypoxia induces K<sub>ATP</sub> channel opening in DAergic cells. However, H<sub>2</sub>O<sub>2</sub> exerts neuroprotection by serving as an alternative source of O<sub>2</sub> through the enhancement of its degradation via the CAT enzyme-mediated pathway. Thus, it counteracts the K<sub>ATP</sub> channels opening.

act by decreasing the activity of GPx and thus augmenting the endogenous level of H<sub>2</sub>O<sub>2</sub>. Consistent with these findings, superfusion of striatal slices with MCS (1 mM) limited the irreversible cortico-striatal field potential depression caused by OGD (12 min) (Figure 3E,F). Once again, the protective effect of MCS superfusion was lost by concomitant bath-application of 3-AT (20 mM), confirming the involvement of CAT in mediating the functional rescue at the synaptic level (Figure 3F). Thus, MCS resulted in neuroprotection both on *in vivo* and *in vitro* ischaemic conditions, through a mechanism which, by blocking GPx, very likely increases endogenous levels of H<sub>2</sub>O<sub>2</sub> and its consequent conversion to O<sub>2</sub> and H<sub>2</sub>O by CAT.

## Can the pharmacological modulation of enzymatic pathways leading to an enhanced H<sub>2</sub>O<sub>2</sub> conversion to O<sub>2</sub> and H<sub>2</sub>O be therapeutic?

The therapeutic potential of modulating the enzymatic pathways leading to H<sub>2</sub>O<sub>2</sub> production and its conversion to O<sub>2</sub> and H<sub>2</sub>O (SOD, GPx, CAT) has been previously investigated via either transgenic or pharmacological intervention tools in both *in vitro* and *in vivo* ischaemic models. The modification of H<sub>2</sub>O<sub>2</sub> signalling might have a key aspect in the expression of neuronal damage during an episode of IR.

### Targeting SOD enzyme

Transgenic mice overexpressing Cu,Zn-SOD enzyme are more resistant to focal brain ischaemia (Yang *et al.*, 1994). However, neither selective deletion nor overexpression of Cu,Zn-SOD affect the outcome of permanent focal brain ischaemia (Chan *et al.*, 1993; Fujimura *et al.*, 2001). On the contrary, Mn-SOD selective deletion worsens the outcome of both transient and permanent MCAo (Murakami *et al.*, 1998; Kim *et al.*, 2002). From these studies it appears that there is the need of a ROS productive reperfusion phase for SOD enzymes to change the fate of the ischaemic tissue (Warner *et al.*, 2004). To our knowledge, no published study has evaluated yet the long-term effects of SOD overexpression on IR outcome and the stability of the achieved protection (Warner *et al.*, 2004). It is known that mice overexpressing Cu,Zn-SOD extracellularly

show an increased tolerance to both focal and global brain ischaemia (Sheng *et al.*, 1999a; 2000), whereas extracellular Cu,Zn-SOD knockout mice show greater damage (Sheng *et al.*, 1999b). In agreement with the data obtained in transgenic animals, it has been shown that polyethylene glycol-conjugated SOD has a potential therapeutic effect in ischaemia (Liu *et al.*, 1989). Moreover, nonpeptidyl SOD-mimetics have proven effective in hypoxia-ischaemia injury in immature rats (Shimizu *et al.*, 2003). However, the short half-life, the reduced capability to penetrate the blood-brain barrier and the antigenicity of SOD have limited its pharmacological use.




### Targeting GPx enzyme

Also, mice overexpressing GPx are more resistant to ischaemic insult (Weisbrot-Lefkowitz *et al.*, 1998; Furling *et al.*, 2000; Ishibashi *et al.*, 2002). An increased infarct size has been observed in GPx knockout mice (Crack *et al.*, 2001), more likely due to excessive H<sub>2</sub>O<sub>2</sub> accumulation in the brain during reperfusion, whereas the cerebroventricular infusion of exogenous GPx was not able to improve the outcome of global IR (Yano *et al.*, 1998). On the other hand, the non-selective GPx mimetic ebselen has protective effects in several ischaemia models (Warner *et al.*, 2004).




### Targeting CAT enzyme

Interestingly, the manipulation of CAT, the other crucial enzyme involved in H<sub>2</sub>O<sub>2</sub> degradation, has given more homogeneous results against the ischaemic insult. In fact, CAT overexpression in the heart of transgenic mice has been shown to provide myocardial protection against IR injury (Mele *et al.*, 2006). Additional strategies based on exogenously administered CAT enzyme (Forsman *et al.*, 1988; Castillo *et al.*, 1990) or on CAT overexpression by viral vector have been used to examine its protective role in IR injury both in *in vitro* and *in vivo* systems (Wang *et al.*, 2003; Gu *et al.*, 2004; Gáspár *et al.*, 2009; Kim *et al.*, 2009; Zemlyak *et al.*, 2009; Ushitora *et al.*, 2010; Chen and Tang, 2011). Of note, systemic infusion of CAT failed to improve neurological deficits after complete ischaemia (Forsman *et al.*, 1988), but resulted in a decrease of myocardial injury following coronary ischaemia (Gardner *et al.*, 1983). In the light of our recent findings demonstrating a CAT-mediated neuroprotective effect of H<sub>2</sub>O<sub>2</sub> in oxygen-deprived brain slices of the




### H<sub>2</sub>O<sub>2</sub> superfusion



### GPx inhibition



### CAT enhancement





### Figure 3

Protective effects of H<sub>2</sub>O<sub>2</sub> superfusion and pharmacological modulation of enzymatic pathways leading to H<sub>2</sub>O<sub>2</sub> production and degradation. (A) In hippocampal slices, H<sub>2</sub>O<sub>2</sub> (3 mM) exogenously bath-applied during OGD (30 min) exposure-induced irreversible loss of fEPSPs (black circles,  $n = 6$ ) caused a complete recovery of synaptic function (white circles,  $n = 6$ ,  $P < 0.0001$ ) in extracellular recordings. (B) Ability of H<sub>2</sub>O<sub>2</sub> to rescue synaptic transmission even when applied 7 min after OGD had started (black circles,  $n = 6$ ,  $P < 0.0001$ ). (C) CAT enzyme is involved in H<sub>2</sub>O<sub>2</sub>-mediated neuroprotection: the CAT inhibitor 3-AT (20 mM) prevented H<sub>2</sub>O<sub>2</sub>-induced recovery of fEPSPs (black circles,  $n = 6$ ,  $P < 0.0001$ ) [A–C modified from Nisticò *et al.* (2008); copyright *BJP*, used with permission]. (D) Representative brain coronal sections (2 mm thick), stained with 2,3,5-triphenyltetrazolium chloride (TTC), showing the infarct area (unstained) in rats treated with the GPx inhibitor MCS (150 mg·kg<sup>-1</sup>) or vehicle (PBS, 1 mL·kg<sup>-1</sup>), i.p., 15 min before transient (2 h) MCAo followed by 22 h reperfusion. Compared with vehicle-treated animals, systemic administration of MCS significantly decreases brain infarct damage produced by transient MCAo in penumbral areas ( $n = 4–6$  rats per experimental group,  $P < 0.05$ ). (E) At the cortico-striatal synaptic transmission, exposure to OGD (7 min) (white circles,  $n = 4$ ) caused a reversible fEPSPs depression, whereas OGD (12 min) caused an irreversible loss of the fEPSPs in extracellular recordings (black circles,  $n = 11$ ). (F) Treatment with MCS (1 mM) 15 min before and during OGD protected synaptic responses from fEPSPs loss (grey circles,  $n = 11$ ,  $P < 0.05$ ). Administration of 3-AT (20 mM, white circles,  $n = 5$ ) reversed the neuroprotection by MCS indicating a CAT-mediated effect [D–F modified from Amantea *et al.* (2009); copyright *Int Rev Neurobiol*, used with permission]. (G) Pretreatment with CAT (500 U·mL<sup>-1</sup>, 15 min) in the presence of OGD (40 min) plus H<sub>2</sub>O<sub>2</sub> (3 mM) (grey circles,  $n = 6$ ) induced a complete recovery of fEPSPs against the irreversible loss caused by OGD (40 min) alone (black circles,  $n = 6$ ,  $P < 0.005$ ). (H) CAT overexpression in the transgenic mice Tg (CAT) (grey circles,  $n = 13$ ) in the presence of H<sub>2</sub>O<sub>2</sub> (3 mM) induced a partial recovery of synaptic response from OGD (40 min) which was significantly different compared with WT mice (black circles,  $n = 10$ ,  $P < 0.05$ ). (I) The figure shows O<sub>2</sub><sup>-</sup> radical formation decrease measured in the CA1 hippocampal region by using fluorescent probe DHE after 1 h of superfusion, in OGD (40 min) exposed-Tg(CAT) slices (lower) as compared with WT group (upper) ( $n = 3$  mice per experimental group,  $P < 0.05$ ). Scale bar: 25 μm [G–I modified from Armogida *et al.* (2011); copyright *IJBP*, used with permission]. In all graphs, data are expressed as means ± SEM; bars indicate the exposure time to compounds and OGD.

substantia nigra, hippocampus, striatum and in an *in vivo* model of transient focal brain ischaemia (Geracitano *et al.*, 2005; Nisticò *et al.*, 2008; Amantea *et al.*, 2009), we have also investigated whether either the exogenous administration or the overexpression of CAT is protective in *in vitro* and *in vivo* brain ischaemic models (Armogida *et al.*, 2011). Along with previous studies, our findings indicate that hippocampal synaptic transmission was restored only when CAT (500 U·mL<sup>-1</sup>, 15 min) was bath-applied before a relative long period of OGD (40 min, that in control condition kills the neurons) in combination with H<sub>2</sub>O<sub>2</sub> (3 mM) (Figure 3G). The CAT-induced neuroprotection was also confirmed in a transgenic mouse overexpressing the enzyme CAT [Tg(CAT)]. In fact, an increased resistance of hippocampal slices against OGD compared with wild-type (WT) animals was observed in the presence of H<sub>2</sub>O<sub>2</sub> (Figure 3H). Furthermore, Tg(CAT) mice showed a decreased infarct size after MCAo compared with WT mice. By using DHE detection, we also observed lower levels of ROS likely reflecting increased ROS metabolism in the Tg(CAT) compared with WT mice 1 h after OGD (40 min) condition (Figure 3I). Interestingly, CAT pretreatment blunted the damaging effect of H<sub>2</sub>O<sub>2</sub> in normoxic conditions. In fact, it decreased fEPSPs depression evoked by repeated applications of H<sub>2</sub>O<sub>2</sub>. Notably, a lower sensitivity to H<sub>2</sub>O<sub>2</sub>-mediated field depression, very likely due to a better functioning of CAT, was indicated by the rightward shift of the H<sub>2</sub>O<sub>2</sub>-induced concentration-response curve in Tg(CAT) compared with WT mice.


#### Targeting SOD and CAT enzymes simultaneously

Conjugation with macromolecules such as liposome-entrapped SOD and CAT (Yusa *et al.*, 1984), polyethylene glycol derivatives (Liu *et al.*, 1989; Armstead *et al.*, 1992; Yabe *et al.*, 1999) or synthetic SOD–CAT mimetics (such as salen–manganese complexes and manganese porphyrins) exhibiting both SOD and CAT activities (Baker *et al.*, 1998; Doctrow

*et al.*, 2002; Zhou *et al.*, 2007; Zhou and Baudry, 2009) has been carried out to facilitate antioxidant compounds delivery to the brain tissue and to increase enzymatic bioavailability and half-life. Either exogenous SOD or CAT delivered into living cells through transduction-mediated cell-penetrating peptide PEP-1 fusion proteins protected myocardium from IR damage in rats. Furthermore, the combined transduction of PEP-1-SOD1 and PEP-1-CAT enhanced their protective effect (Huang *et al.*, 2011). Interestingly, targeted cell-penetrating CAT derivative with enhanced peroxisome targeting efficiency (CAT-SKL) delivery also protected neonatal rat myocytes from IR injury (Undyala *et al.*, 2011). Moreover, the administration of SOD/CAT mimetics before ischaemia has been reported to be neuroprotective in animal model of brain ischaemia (Sharma and Gupta, 2007).

#### H<sub>2</sub>O<sub>2</sub> as a preconditioning factor in neuroprotection

Another important aspect to consider is the implication of H<sub>2</sub>O<sub>2</sub> in the ischaemic preconditioning (IPC) phenomenon by which a brief sub-lethal ischaemic episode induces tolerance against subsequent prolonged ischaemia that usually induces lethal damage. Cardioprotective (Yaguchi *et al.*, 2003) and neuroprotective effects of H<sub>2</sub>O<sub>2</sub> have been observed in several *in vitro* models of IPC (Furuichi *et al.*, 2005; Xiao-Qing *et al.*, 2005). In fact, it has been demonstrated that the generation of H<sub>2</sub>O<sub>2</sub> during brief OGD (10 min) induces IPC in rat primary cultured cortex neurons (Furuichi *et al.*, 2005). In addition, H<sub>2</sub>O<sub>2</sub>, at low concentration (10 μM), can protect PC12 cell line against DA-induced apoptosis most likely by restoring mitochondrial function (Xiao-Qing *et al.*, 2005). Accordingly, in a study conducted by Simerabet *et al.* (2008), the stereotactic *in situ* infusion of H<sub>2</sub>O<sub>2</sub> (2 mM) decreased rat cerebral infarct size (cortical area) 24 h after MCAo (1 h), suggesting an involvement of H<sub>2</sub>O<sub>2</sub> during the induction



**Figure 4**

Working model of proposed enzymatic targets of H<sub>2</sub>O<sub>2</sub> metabolism for the treatment of brain ischaemia. A therapeutic effect against brain ischaemia could be achieved by the pharmacological modulation of H<sub>2</sub>O<sub>2</sub> producing (SOD) and degrading enzymes (CAT and GPx). In *in vitro* and *in vivo* brain ischaemia models, neuroprotection is afforded via CAT pathway activation mainly through two mechanisms: supplementary production of O<sub>2</sub> to compensate for the lack of O<sub>2</sub> and detoxification from H<sub>2</sub>O<sub>2</sub> derived •OH radical associated-oxidative stress.

phase of IPC (Simerabet *et al.*, 2008). Moreover, in another study carried out by Chang *et al.* (2008), exogenous low concentration of H<sub>2</sub>O<sub>2</sub> (15 µM) may contribute to IPC against OGD (24 h) in rat primary neurons by increasing HIF-1α protein expression.

## Conclusions and future directions

At present, ischaemic stroke is the second-leading cause of death worldwide and represents a serious unmet medical need. Although therapeutic interventions such as thrombolytic therapy with recombinant tissue plasminogen activator have been shown to be effective (Wechsler, 2011), a ‘neuroprotective strategy’, preventing or lessening the damaging components of the ischaemic cascade, has not been unequivocally demonstrated in clinical trials (Fisher, 2011). Failure of such programmes could be attributable to both insufficient preclinical models and clinical designs (Fisher, 2011; Macrae, 2011). The data discussed in the present review suggest exploiting possible neuroprotective strategies based on targeting H<sub>2</sub>O<sub>2</sub> metabolism in stroke. In spite of the fact that no clinical studies have been conducted evaluating the therapeutic usage of drugs targeting H<sub>2</sub>O<sub>2</sub> metabolism in stroke, the experimental observations obtained so far by our and other groups support the idea that H<sub>2</sub>O<sub>2</sub> might represent an attractive target for the development of novel therapies to diminish the burden of brain ischaemia. Thus, according to our hypothesis, neuroprotection in ischaemia could be principally obtained by two mechanisms when the H<sub>2</sub>O<sub>2</sub> metabolism is pharmacologically manipulated to boost CAT pathway: (i) one mechanism produces a supplementary source of O<sub>2</sub> to partially compensate for the lack of O<sub>2</sub> that occurs in the ischaemic cerebral tissue (this role could be more prominent in the ischaemic phase); and (ii) the other is

characterized by enhanced CAT which detoxifies more easily brain tissue from ROS, thus decreasing the accumulation of H<sub>2</sub>O<sub>2</sub> and the radical •OH derived from H<sub>2</sub>O<sub>2</sub> excess (this role could be more prominent during the reperfusion phase when there is an increased generation of ROS) (Figure 4). Therefore, pharmacological agents effective in the treatment of brain ischaemia should obtain an increase in the level of H<sub>2</sub>O<sub>2</sub> by blocking GPx preferably associated to an increased enzymatic activity of SOD and CAT. Indeed, in the study conducted by Avshalumov *et al.* (2004), either GPx or CAT inhibition enhanced H<sub>2</sub>O<sub>2</sub> toxicity in rat hippocampal slices, confirming the importance of the integrity of glial antioxidant network and supporting further CAT pathway enhancement rather than GPx inhibition in the prevention of pathophysiological consequences.

In addition, of paramount importance for the therapeutic potential of such treatment is the decrease of the damaging effects of H<sub>2</sub>O<sub>2</sub> in normoxic conditions (e.g. by using potent antioxidant agents) and the rapid boost of H<sub>2</sub>O<sub>2</sub> enzymatic degradation to O<sub>2</sub> through the CAT pathway (e.g. by using efficient SOD-CAT mimetics). We believe that the therapeutic potential of drugs targeting H<sub>2</sub>O<sub>2</sub> metabolism needs to be explored in depth at a preclinical level in order to transform their theoretical use in brain ischaemia in a true clinical application. A future challenge in the hands of neuroscientists is to validate an H<sub>2</sub>O<sub>2</sub> signalling-mediated pharmacological treatment of stroke.

## Acknowledgements

We are grateful to Dr Maria Lo Ponte for her linguistic revision of the manuscript. We also wish to thank the Reviews Editor, Dr Mike Curtis, and the anonymous co-Editor and reviewers for their perceptive and helpful comments.

## Conflict of interest

The authors state no conflict of interest with respect to the authorship and/or publication of this article.

## References

- Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1–S324.
- Amantea D, Marrone MC, Nisticò R, Federici M, Bagetta G, Bernardi G *et al.* (2009). Oxidative stress in stroke pathophysiology validation of hydrogen peroxide metabolism as a pharmacological target to afford neuroprotection. *Int Rev Neurobiol* 85: 363–374.
- Antunes F, Cadenas E (2000). Estimation of H<sub>2</sub>O<sub>2</sub> gradients across biomembranes. *FEBS Lett* 475: 121–126.
- Appleman D, Heim WG, Pyfrom HT (1956). Effects of 3-amino-1, 2, 4-triazole (AT) on catalase and other compounds. *Am J Physiol* 186: 19–23.
- Armogida M, Spalloni A, Amantea D, Nutini M, Petrelli F, Longone P *et al.* (2011). On the protective role of catalase against cerebral ischemia *in vitro* and *in vivo*. *Int J Immunopathol Pharmacol* 24: 735–747.
- Armstead WM, Mirro R, Thelin OP, Shibata M, Zuckerman SL, Shanklin DR *et al.* (1992). Polyethylene glycol superoxide dismutase and catalase attenuate increased blood-brain barrier permeability after ischemia in piglets. *Stroke* 23: 755–762.
- Auerbach JM, Segal M (1997). Peroxide modulation of slow onset potentiation in rat hippocampus. *J Neurosci* 17: 8695–8701.
- Avshalumov MV, Chen BT, Marshall SP, Peña DM, Rice ME (2003). Glutamate-dependent inhibition of dopamine release in striatum is mediated by a new diffusible messenger, H<sub>2</sub>O<sub>2</sub>. *J Neurosci* 23: 2744–2750.
- Avshalumov MV, MacGregor DG, Sehgal LM, Rice ME (2004). The glial antioxidant network and neuronal ascorbate: protective yet permissive for H(2)O(2) signaling. *Neuron Glia Biol* 1: 365–376.
- Avshalumov MV, Chen BT, Kóos T, Tepper JM, Rice ME (2005). Endogenous hydrogen peroxide regulates the excitability of midbrain dopamine neurons via ATP-sensitive potassium channels. *J Neurosci* 25: 4222–4231.
- Avshalumov MV, Patel JC, Rice ME (2008). AMPA receptor dependent H<sub>2</sub>O<sub>2</sub> generation in striatal medium spiny neurons, but not dopamine axons: one source of a retrograde signal that can inhibit dopamine release. *J Neurophysiol* 100: 1590–1601.
- Baker K, Bucay-Marcus C, Huffman C, Kruk H, Malfroy B, Doctrow SR (1998). Synthetic combined superoxide dismutase/catalase mimetics are protective as a delayed treatment in a rat stroke model: a key role for reactive oxygen species in ischemic brain injury. *J Pharmacol Exp Ther* 284: 215–221.
- Bao L, Avshalumov MV, Patel JC, Lee CR, Miller EW, Chang CJ *et al.* (2009). Mitochondria are the source of hydrogen peroxide for dynamic brain-cell signaling. *J Neurosci* 29: 9002–9010.
- Bienert GP, Schjoerring JK, Jahn TP (2006). Membrane transport of hydrogen peroxide. *Biochim Biophys Acta* 1758: 994–1003.
- Bienert GP, Møller AL, Kristiansen KA, Schulz A, Møller IM, Schjoerring JK *et al.* (2007). Specific aquaporins facilitate the diffusion of hydrogen peroxide across membranes. *J Biol Chem* 282: 1183–1192.
- Boveris A, Chance B (1973). The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. *Biochem J* 134: 707–716.
- Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y *et al.* (2004). Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. *Science* 303: 2011–2015.
- Cai H (2005). Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. *Cardiovasc Res* 68: 26–36.
- Castillo M, Toledo-Pereyra LH, Shapiro E, Guerra E, Prough D, Frantzi P (1990). Protective effect of allopurinol, catalase, or superoxide dismutase in ischemic rat liver. *Transplant Proc* 22: 490–491.
- Chan PH, Kamii H, Yang GY, Gafni J, Epstein CJ, Carlson E *et al.* (1993). Brain infarction is not reduced in SOD-1 transgenic mice after a permanent focal cerebral ischemia. *Neuroreport* 5: 293–296.
- Chang S, Jiang X, Zhao C, Lee C, Ferriero DM (2008). Exogenous low dose hydrogen peroxide increases hypoxia-inducible factor-1alpha protein expression and induces preconditioning protection against ischemia in primary cortical neurons. *Neurosci Lett* 441: 134–138.
- Chaudiere J, Wilhelmsen EC, Tappel AL (1984). Mechanism of selenium-glutathione peroxidase and its inhibition by mercaptocarboxylic acids and other mercaptans. *J Biol Chem* 259: 1043–1050.
- Chen B, Tang L (2011). Protective effects of catalase on retinal ischemia/reperfusion injury in rats. *Exp Eye Res* 93: 599–606.
- Chen BT, Avshalumov MV, Rice ME (2001). H<sub>2</sub>O<sub>2</sub> is a novel, endogenous modulator of synaptic dopamine release. *J Neurophysiol* 85: 2468–2476.
- Chen L, Xu B, Liu L, Luo Y, Yin J, Zhou H *et al.* (2010). Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. *Lab Invest* 90: 762–773.
- Cohen G (1994). Enzymatic/nonenzymatic sources of oxyradicals and regulation of antioxidant defenses. *Ann N Y Acad Sci* 738: 8–14.
- Colton CA, Fagni L, Gilbert D (1989). The action of hydrogen peroxide on paired pulse and long-term potentiation in the hippocampus. *Free Radic Biol Med* 7: 3–8.
- Crack PJ, Taylor JM, Flentjar NJ, de Haan J, Hertzog P, Iannello RC *et al.* (2001). Increased infarct size and exacerbated apoptosis in the glutathione peroxidase-1 (Gpx-1) knockout mouse brain in response to ischemia/reperfusion injury. *J Neurochem* 78: 1389–1399.
- D’Autréaux B, Toledano MB (2007). ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. *Nat Rev Mol Cell Biol* 8: 813–824.
- Doctrow SR, Huffman K, Marcus CB, Tocco G, Malfroy E, Adinolfi CA *et al.* (2002). Salen-manganese complexes as catalytic scavengers of hydrogen peroxide and cytoprotective agents: structure-activity relationship studies. *J Med Chem* 45: 4549–4558.
- Dringen R, Pawlowski PG, Hirrlinger J (2005). Peroxide detoxification by brain cells. *J Neurosci Res* 79: 157–165.
- Durukan A, Tatlisumak T (2009). Ischemic stroke in mice and rats. *Methods Mol Biol* 573: 95–114.
- Farr CH (1988). Physiological and biochemical responses to intravenous hydrogen peroxide in man. *J Adv Med* 1: 113–129.

- Finkel T (2011). Signal transduction by reactive oxygen species. *J Cell Biol* 194: 7–15.
- Finney JW, Urschel HC, Balla GA, Race GJ, Jay BE, Pingree HP *et al.* (1967). Protection of the ischemic heart with DMSO alone or DMSO with hydrogen peroxide. *Ann N Y Acad Sci* 141: 231–241.
- Fisher M (2011). New approaches to neuroprotective drug development. *Stroke* 42: S24–S27.
- Flamm ES, Demopoulos HB, Seligman ML, Poser RG, Ranoshoff J (1978). Free radicals in cerebral ischemia. *Stroke* 9: 445–447.
- Forsman M, Fleischer JE, Milde JH, Stehen PA, Michenfelder JD (1988). Superoxide dismutase and catalase failed to improve neurologic outcome after complete cerebral ischemia in the dog. *Acta Anaesthesiol Scand* 32: 152–155.
- Fowler JC (1997). Hydrogen peroxide opposes the hypoxic depression of evoked synaptic transmission in rat hippocampal slices. *Brain Res* 766: 255–258.
- French LK, Horowitz BZ, McKeown NJ (2010). Hydrogen peroxide ingestion associated with portal venous gas and treatment with hyperbaric oxygen: a case series and review of the literature. *Clin Toxicol* 48: 533–538.
- Fridovich I (1995). Superoxide radical and superoxide dismutases. *Annu Rev Biochem* 64: 97–112.
- Fujimura M, Morita-Fujimura Y, Noshita N, Sugawara T, Kawase M, Chan PH (2000). The cytosolic antioxidant copper/zinc-superoxide dismutase prevents the early release of mitochondrial cytochrome c in ischemic brain after transient focal cerebral ischemia in mice. *J Neurosci* 20: 2817–2824.
- Fujimura M, Morita-Fujimura Y, Copin J, Yoshimoto T, Chan PH (2001). Reduction of copper, zinc-superoxide dismutase in knockout mice does not affect edema or infarction volumes and the early release of mitochondrial cytochrome c after permanent focal cerebral ischemia. *Brain Res* 889: 208–213.
- Furling D, Ghribi O, Lahsaini A, Mirault ME, Massicotte G (2000). Impairment of synaptic transmission by transient hypoxia in hippocampal slices: improved recovery in glutathione peroxidase transgenic mice. *Proc Natl Acad Sci U S A* 97: 4351–4356.
- Furuichi T, Liu W, Shi H, Miyake M, Liu KJ (2005). Generation of hydrogen peroxide during brief oxygen-glucose deprivation induces preconditioning neuronal protection in primary cultured neurons. *J Neurosci Res* 79: 816–824.
- Gardner TJ, Stewart JR, Casale AS, Downey JM, Chambers DE (1983). Reduction of myocardial ischemic injury with oxygen-derived free radical scavengers. *Surgery* 94: 423–427.
- Gáspár T, Domoki F, Lenti L, Institoris A, Snipes JA, Bari F *et al.* (2009). Neuroprotective effect of adenoviral catalase gene transfer in cortical neuronal cultures. *Brain Res* 1270: 1–9.
- Geracitano R, Tozzi A, Berretta N, Florenzano F, Guatteo E, Viscomi MT *et al.* (2005). Protective role of hydrogen peroxide in oxygen-deprived dopaminergic neurones of the rat substantia nigra. *J Physiol* 568: 97–110.
- Gerich FJ, Funke F, Hildebrandt B, Fasshauer M, Müller M (2009). H<sub>2</sub>O<sub>2</sub>-mediated modulation of cytosolic signaling and organelle function in rat hippocampus. *Pflügers Arch* 458: 937–952.
- Giaginis C, Tsourouflis G, Theocharis S (2008). Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury. *Curr Mol Med* 8: 562–579.
- Giorgio M, Trinei M, Migliaccio E, Pelicci PG (2007). Hydrogen peroxide: a metabolic by-product or a common mediator of ageing signals? *Nat Rev Mol Cell Biol* 8: 722–728.
- Góth L (2006). [The hydrogen peroxide paradox]. *Orv Hetil* 147: 887–893.
- Gough DR, Cotter TG (2011). Hydrogen peroxide: a Jekyll and Hyde signalling molecule. *Cell Death Dis* 2: e213.
- Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF (1978). Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells *in vitro*. *Mol Pharmacol* 14: 644–653.
- Green S (1998). Oxygenation therapy: unproven treatments for cancer and AIDS. *Sci Rev Altern Med* 2: 6–13. Available at: <http://www.quackwatch.org/01QuackeryRelatedTopics/Cancer/oxygen.html> (accessed 27 July 2011).
- Groeger G, Quiney C, Cotter TG (2009). Hydrogen peroxide as a cell-survival signaling molecule. *Antioxid Redox Signal* 11: 2655–2671.
- Gu W, Zhao H, Yenari MA, Sapolsky RM, Steinberg GK (2004). Catalase over-expression protects striatal neurons from transient focal cerebral ischemia. *Neuroreport* 15: 413–416.
- Halliwell B (1992). Reactive oxygen species and the central nervous system. *J Neurochem* 59: 1609–1623.
- Halliwell B (1999). Antioxidant defence mechanisms: from the beginning to the end (of the beginning). *Free Radic Res* 31: 261–272.
- Halliwell B, Gutteridge JMC (1999). Free radicals, other reactive species and disease. In: Halliwell B, Gutteridge JMC (eds). *Free Radicals in Biology and Medicine*. Clarendon Press: Oxford, pp. 617–783.
- Halliwell B, Clement MV, Long LH (2000). Hydrogen peroxide in the human body. *FEBS Lett* 486: 10–13.
- van der Horst A, Tertoolen LG, de Vries-Smits LM, Frye RA, Medema RH, Burgering BM (2004). FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). *J Biol Chem* 279: 28873–28879.
- Huang GQ, Wang JN, Tang JM, Zhang L, Zheng F, Yang JY *et al.* (2011). The combined transduction of copper, zinc-superoxide dismutase and catalase mediated by cell-penetrating peptide, PEP-1, to protect myocardium from ischemia-reperfusion injury. *J Transl Med* 9: 73.
- Hyslop PA, Zhang Z, Pearson DV, Phebus LA (1995). Measurement of striatal H<sub>2</sub>O<sub>2</sub> by microdialysis following global forebrain ischemia and reperfusion in the rat: correlation with the cytotoxic potential of H<sub>2</sub>O<sub>2</sub> *in vitro*. *Brain Res* 671: 181–186.
- Ishibashi N, Prokopenko O, Weisbrot-Lefkowitz M, Reuhl KR, Mirochnitchenko O (2002). Glutathione peroxidase inhibits cell death and glial activation following experimental stroke. *Brain Res Mol Brain Res* 109: 34–44.
- Kamsler A, Segal M (2003). Hydrogen peroxide modulation of synaptic plasticity. *J Neurosci* 23: 269–276.
- Katsuki H, Nakanishi C, Saito H, Matsuki N (1997). Biphasic effect of hydrogen peroxide on field potentials in rat hippocampal slices. *Eur J Pharmacol* 337: 213–218.
- Kaundal RK, Sharma SS (2010). Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. *Drug News Perspect* 23: 241–256.



- Kim DW, Jeong HJ, Kang HW, Shin MJ, Sohn EJ, Kim MJ *et al.* (2009). Transduced human PEP-1-catalase fusion protein attenuates ischemic neuronal damage. *Free Radic Biol Med* 47: 941–952.
- Kim GW, Kondo T, Noshita N, Chan PH (2002). Manganese superoxide dismutase deficiency exacerbates cerebral infarction after focal cerebral ischemia/reperfusion in mice: implications for the production and role of superoxide radicals. *Stroke* 33: 809–815.
- Kirino T (1982). Delayed neuronal death in the gerbil hippocampus following ischemia. *Brain Res* 239: 57–69.
- Klann E, Thiels E (1999). Modulation of protein kinases and protein phosphatases by reactive oxygen species: implications for hippocampal synaptic plasticity. *Prog Neuropsychopharmacol Biol Psychiatry* 23: 359–376.
- Lees GJ, Leong W (1995). The sodium-potassium ATPase inhibitor ouabain is neurotoxic in the rat substantia nigra and striatum. *Neurosci Lett* 188: 113–116.
- Lei B, Adachi N, Arai T (1998). Measurement of the extracellular H<sub>2</sub>O<sub>2</sub> in the brain by microdialysis. *Brain Res Brain Res Protoc* 3: 33–36.
- Lipsanen A, Jolkkonen J (2011). Experimental approaches to study functional recovery following cerebral ischemia. *Cell Mol Life Sci* 68: 3007–3017.
- Lipton P (1999). Ischemic cell death in brain neurons. *Physiol Rev* 79: 1431–1568.
- Liu TH, Beckman JS, Freeman BA, Hogan EL, Hsu CY (1989). Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. *Am J Physiol Heart Circ Physiol* 256: H589–H593.
- Love IN (1888). Peroxide of Hydrogen as a remedial agent. *JAMA* 10: 262–265.
- Ma HP (2011). Hydrogen peroxide stimulates the epithelial sodium channel through a phosphatidylinositol 3-kinase-dependent pathway. *J Biol Chem* 286: 32444–32453.
- Macrae I (2011). Preclinical stroke research – advantages and disadvantages of the most common rodent models of focal ischaemia. *Br J Pharmacol* 164: 1062–1078.
- Margoliash E, Novogrodsky A (1958). A study of the inhibition of catalase by 3-amino-1,2,4-triazole. *Biochem J* 68: 468–475.
- Mele J, Van Remmen H, Vijg J, Richardson A (2006). Characterization of transgenic mice that overexpress both copper zinc superoxide dismutase and catalase. *Antioxid Redox Signal* 8: 628–638.
- Mercuri NB, Bonci A, Calabresi P, Stratta F, Bernardi G (1994). Responses of rat mesencephalic dopaminergic neurons to a prolonged period of oxygen deprivation. *Neuroscience* 63: 757–764.
- Miller EW, Albers AE, Pralle A, Isacoff EY, Chang CJ (2005). Boronate-based fluorescent probes for imaging cellular hydrogen peroxide. *J Am Chem Soc* 127: 16652–16659.
- Miller EW, Tulyathan O, Isacoff EY, Chang CJ (2007). Molecular imaging of hydrogen peroxide produced for cell signaling. *Nat Chem Biol* 3: 263–267.
- Miller EW, Dickinson BC, Chang CJ (2010). Aquaporin-3 mediates hydrogen peroxide uptake to regulate downstream intracellular signaling. *Proc Natl Acad Sci U S A* 107: 15681–15686.
- Mishina NM, Tyurin-Kuzmin PA, Markvicheva KN, Vorotnikov AV, Tkachuk VA, Laketa V *et al.* (2011). Does cellular hydrogen peroxide diffuse or act locally? *Antioxid Redox Signal* 14: 1–7.
- Murakami K, Kondo T, Kawasr M, Li Y, Sato S, Chen SF *et al.* (1998). Mitochondrial susceptibility to oxidative stress exacerbates cerebral infarction that follows permanent focal cerebral ischemia in mutant mice with manganese superoxide dismutase deficiency. *J Neurosci* 18: 205–213.
- Nisticò R, Piccirilli S, Cucchiaroni ML, Armogida M, Guatteo E, Giampà C *et al.* (2008). Neuroprotective effect of hydrogen peroxide on an *in vitro* model of brain ischaemia. *Br J Pharmacol* 153: 1022–1029.
- Oliveira-Marques V, Marinho HS, Cyrne L, Antunes F (2009). Role of hydrogen peroxide in NF- $\kappa$ B activation: from inducer to modulator. *Antioxid Redox Signal* 11: 2223–2243.
- Oliver TH, Cantab BC, Murphy DV (1920). Influenzal pneumonia: the intravenous injection of hydrogen peroxide. *Lancet* 1: 432–433.
- Pellmar TC (1987). Peroxide alters neuronal excitability in the CA1 region of guinea-pig hippocampus *in vitro*. *Neuroscience* 23: 447–456.
- Pulsinelli WA, Brierley JB, Plum F (1982). Temporal profile of neuronal damage in a model of transient forebrain ischemia. *Ann Neurol* 11: 491–498.
- Rhee SG (2006). H<sub>2</sub>O<sub>2</sub>, a necessary evil for cell signaling. *Science* 312: 1882–1883.
- Rhee SG, Bae YS, Lee SR, Kwon J (2000). Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. *Sci STKE* 2000: pe1.
- Rice ME (2011). H<sub>2</sub>O<sub>2</sub>: a dynamic neuromodulator. *Neuroscientist* 17: 389–406.
- Schoenbein CF (1856). On ozone and ozonic actions in mushrooms. *Phil Mag* 11: 137–141.
- Sen CK, Packer L (1996). Antioxidant and redox regulation of gene transcription. *FASEB J* 10: 709–720.
- Sharma SS, Gupta S (2007). Neuroprotective effect of MnTMPyP, a superoxide dismutase/catalase mimetic in global cerebral ischemia is mediated through reduction of oxidative stress and DNA fragmentation. *Eur J Pharmacol* 561: 72–79.
- Sheng H, Bart RD, Oury TD, Pearlstein RD, Crapo JD, Warner DS (1999a). Mice overexpressing extracellular superoxide dismutase have increased resistance to focal cerebral ischemia. *Neuroscience* 88: 185–191.
- Sheng H, Brody T, Pearlstein RD, Crapo J, Warner DS (1999b). Extracellular superoxide dismutase deficient mice have decreased resistance to focal cerebral ischemia. *Neurosci Lett* 267: 13–17.
- Sheng H, Kudo M, Mackensen GB, Pearlstein RD, Crapo JD, Warner DS (2000). Mice overexpressing extracellular superoxide dismutase have increased tolerance to global cerebral ischemia. *Exp Neurol* 163: 392–398.
- Shimizu K, Rajapakse N, Horiguchi T, Payne RM, Busija DW (2003). Protective effect of a new nonpeptidyl mimetic of SOD, M40401, against focal cerebral ischemia in the rat. *Brain Res* 963: 8–14.
- Simerabet M, Robin E, Aristi I, Adamczyk S, Tavernier B, Vallet B *et al.* (2008). Preconditioning by an *in situ* administration of hydrogen peroxide: involvement of reactive oxygen species and mitochondrial ATP-dependent potassium channel in a cerebral ischemia-reperfusion model. *Brain Res* 1240: 177–184.
- Sims NR, Anderson MF (2002). Mitochondrial contributions to tissue damage in stroke. *Neurochem Int* 40: 511–526.

- Smith ML, Auer RN, Siesjö BK (1984). The density and distribution of ischemic brain injury in the rat following 2-10 min of forebrain ischemia. *Acta Neuropathol* 64: 319-332.
- Stone JR, Yang S (2006). Hydrogen peroxide: a signaling messenger. *Antioxid Redox Signal* 8: 243-270.
- St-Pierre J, Drori S, Uldry M, Selvaggi JM, Rhee J, Jäger S *et al.* (2006). Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. *Cell* 127: 397-408.
- Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T (1995). Requirement for generation of H<sub>2</sub>O<sub>2</sub> for platelet-derived growth factor signal transduction. *Science* 270: 296-299.
- Thénard LJ (1818). Observations sur des nouvelles combinaisons entre l'oxygène et divers acides. *Ann Phys* 8: 306-312.
- Tipton KF (1968). The reaction pathway of pig brain mitochondrial monoamine oxidase. *Eur J Biochem* 5: 316-320.
- Tipton KF, Boyce S, O'Sullivan J, Davey GP, Healy J (2004). Monoamine oxidases: certainties and uncertainties. *Curr Med Chem* 11: 1965-1982.
- Topper JN, Cai J, Falb D, Gimbrone MA Jr (1996). Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. *Proc Natl Acad Sci U S A* 93: 10417-10422.
- Traystman RJ, Kirsch JR, Koehler RC (1991). Oxygen radical mechanisms of brain injury following ischemia and reperfusion. *J Appl Physiol* 71: 1185-1195.
- Undyala V, Terlecky SR, Vander Heide RS (2011). Targeted intracellular catalase delivery protects neonatal rat myocytes from hypoxia-reoxygenation and ischemia-reperfusion injury. *Cardiovasc Pathol* 20: 272-280.
- Urschel HC Jr (1967). Progress in cardiovascular surgery. Cardiovascular effects of hydrogen peroxide: current status. *Dis Chest* 51: 180-192.
- Ushitora M, Sakurai F, Yamaguchi T, Nakamura S, Kondoh M, Yagi K *et al.* (2010). Prevention of hepatic ischemia-reperfusion injury by pre-administration of catalase-expressing adenovirus vectors. *J Control Release* 142: 431-437.
- Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007). Free radicals and antioxidants in normal physiological functions and human disease. *Int J Biochem Cell Biol* 39: 44-84.
- Vanella A, Di Giacomo C, Sorrenti V, Russo A, Castorina C, Campisi A *et al.* (1993). Free radical scavenger depletion in post-ischemic reperfusion brain damage. *Neurochem Res* 18: 1337-1340.
- Veal EA, Day AM, Morgan BA (2007). Hydrogen peroxide sensing and signaling. *Mol Cell* 26: 1-14.
- Walton K, Fulton B (1983). Hydrogen peroxide as a source of molecular oxygen for *in vitro* mammalian CNS preparations. *Brain Res* 278: 387-393.
- Wang H, Cheng E, Brooke S, Chang P, Sapolsky R (2003). Over-expression of antioxidant enzymes protects cultured hippocampal and cortical neurons from necrotic insults. *J Neurochem* 87: 1527-1534.
- Warner DS, Sheng H, Batinić-Haberle I (2004). Oxidants, antioxidants and the ischemic brain. *J Exp Biol* 207: 3221-3231.
- Watt BE, Proudfoot AT, Vale JA (2004). Hydrogen peroxide poisoning. *Toxicol Rev* 23: 51-57.
- Wechsler LR (2011). Intravenous thrombolytic therapy for acute ischemic stroke. *N Engl J Med* 364: 2138-2146.
- Weisbrot-Lefkowitz M, Reuhl K, Perry B, Chan PH, Inouye M, Mirochnitchenko O (1998). Overexpression of human glutathione peroxidase protects transgenic mice against focal cerebral ischemia/reperfusion damage. *Brain Res Mol Brain Res* 53: 333-338.
- White BC, Sullivan JM, DeGracia DJ, O'Neil BJ, Neumar RW, Grossman LI *et al.* (2000). Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. *J Neurol Sci* 179: 1-33.
- Willhelm SF (1989). Personal Communication from Fr. Richard Willhelm. Enlightened Catholic Health Organization (ECHO): Naples, FL.
- Winterbourn CC (2008). Reconciling the chemistry and biology of reactive oxygen species. *Nat Chem Biol* 4: 278-286.
- Wolffenstein R (1894). Concentration und Destillation von Wasserstoffsuperoxyd. *Ber Dtsch Chem Ges* 27: 3307-3312.
- Xiao-Qing T, Jun-Li Z, Yu C, Jian-Qiang F, Pei-Xi C (2005). Hydrogen peroxide preconditioning protects PC12 cells against apoptosis induced by dopamine. *Life Sci* 78: 61-66.
- Yabe Y, Nishikawa M, Tamada A, Takakura Y, Hashida M (1999). Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives. *J Pharmacol Exp Ther* 289: 1176-1184.
- Yaguchi Y, Satoh H, Wakahara N, Katoh H, Uehara A, Terada H *et al.* (2003). Protective effects of hydrogen peroxide against ischemia/reperfusion injury in perfused rat hearts. *Circ J* 67: 253-258.
- Yang G, Chan PH, Chen J, Carlson E, Chen SF, Weinstein P *et al.* (1994). Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. *Stroke* 25: 165-170.
- Yano T, Ushijima K, Terasaki H (1998). Failure of glutathione peroxidase to reduce transient ischemic injury in the rat hippocampal CA1 subfield. *Resuscitation* 39: 91-98.
- Yusa T, Crapo JD, Freeman BA (1984). Liposome-mediated augmentation of brain SOD and catalase inhibits CNS O<sub>2</sub> toxicity. *J Appl Physiol* 57: 1674-1681.
- Zemlyak I, Brooke SM, Singh MH, Sapolsky RM (2009). Effects of overexpression of antioxidants on the release of cytochrome c and apoptosis-inducing factor in the model of ischemia. *Neurosci Lett* 453: 182-185.
- Zhou M, Baudry M (2009). EUK-207, a superoxide dismutase/catalase mimetic, is neuroprotective against oxygen/glucose deprivation-induced neuronal death in cultured hippocampal slices. *Brain Res* 1247: 28-37.
- Zhou M, Dominguez R, Baudry M (2007). Superoxide dismutase/catalase mimetics but not MAP kinase inhibitors are neuroprotective against oxygen/glucose deprivation-induced neuronal death in hippocampus. *J Neurochem* 103: 2212-2223.